Please try another search
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. EirGenix Inc. was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.
Name | Age | Since | Title |
---|---|---|---|
Lee-Cheng Liu | - | 2012 | Founder, President, CEO, CSO & Chairman |
Ming-Thaur Chang | - | 2019 | Independent Director |
Hsiu-Hui Chen | - | 2016 | Representative Director |
Ming-Shen Chen | - | 2016 | Independent Director |
Fu-Shiow Yin | - | 2016 | Independent Director |
Cheng-Yu Cheng | - | 2013 | Representative Director |
Weng Ku-Sung | - | - | Director |
Po-Chih Chen | - | 2022 | Independent Director |
Yu-Ting Chen | - | 2022 | Director |
Chun-Fu Lu | 53 | 2023 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review